急性心肌梗死合并心源性休克患者的PCI策略
该多中心试验随机分配706例多支血管病变的急性心肌梗死合并心源性休克患者,比较初始仅对罪犯病变行PCI(非罪犯病变可分期血运重建)与即刻多支血管PCI两种策略。主要终点为随机化后30天内死亡或需肾脏替代治疗的严重肾衰竭复合终点。结果显示,罪犯病变仅PCI组主要终点发生率为45.9%(158/344),多支血管PCI组为55.4%(189/341),相对风险0.83(95%CI 0.71-0.96;P=0.01)。罪犯病变仅PCI组死亡相对风险为0.84(95%CI 0.72-0.98;P=0.03),肾脏替代治疗相对风险为0.71(95%CI 0.49-1.03;P=0.07)。两组在血流动力学稳定时间、儿茶酚胺治疗风险及持续时间、肌钙蛋白T和肌酸激酶水平、出血和卒中发生率方面无显著差异。
要点
- 多支血管病变的急性心肌梗死合并心源性休克患者,初始仅对罪犯病变行PCI组30天死亡或需肾脏替代治疗的严重肾衰竭复合终点发生率为45.9%(158/344),低于即刻多支血管PCI组的55.4%(189/341),相对风险0.83(95%CI 0.71-0.96;P=0.01)。
- 罪犯病变仅PCI组死亡相对风险为0.84(95%CI 0.72-0.98;P=0.03),低于多支血管PCI组。
- 肾脏替代治疗相对风险为0.71(95%CI 0.49-1.03;P=0.07),两组间未达统计学显著差异。
- 两组在血流动力学稳定时间、儿茶酚胺治疗风险及持续时间、肌钙蛋白T和肌酸激酶水平、出血和卒中发生率方面无显著差异。
适用人群与场景
- 多支血管病变的急性心肌梗死合并心源性休克患者,随机分配706例。
处置流程与药物剂量
- 初始仅对罪犯病变行PCI,非罪犯病变可选择分期血运重建。
- 或即刻多支血管PCI。
研究设计与关键结果
- 多中心随机试验,纳入706例多支血管病变的急性心肌梗死合并心源性休克患者,比较初始仅罪犯病变PCI(可分期处理非罪犯病变)与即刻多支血管PCI。
- 30天主要复合终点(死亡或需肾脏替代治疗的严重肾衰竭):罪犯病变仅PCI组158/344(45.9%) vs 多支血管PCI组189/341(55.4%),相对风险0.83(95%CI 0.71-0.96;P=0.01)。
- 死亡相对风险:罪犯病变仅PCI组 vs 多支血管PCI组为0.84(95%CI 0.72-0.98;P=0.03)。
- 肾脏替代治疗相对风险:罪犯病变仅PCI组 vs 多支血管PCI组为0.71(95%CI 0.49-1.03;P=0.07)。
- 血流动力学稳定时间、儿茶酚胺治疗风险及持续时间、肌钙蛋白T和肌酸激酶水平、出血和卒中发生率两组间无显著差异。
证据类型、等级与局限
- 证据类型:多中心随机对照试验(CULPRIT-SHOCK,NCT01927549)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于多支血管病变的急性心肌梗死合并心源性休克患者,作者结论认为初始仅对罪犯病变行PCI较即刻多支血管PCI可降低30天死亡或需肾脏替代治疗的严重肾衰竭复合终点风险。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: In patients who have acute myocardial infarction with cardiogenic shock, early revascularization of the culprit artery by means of percutaneous coronary intervention (PCI) improves outcomes. However, the majority of patients with cardiogenic shock have multivessel disease, and whether PCI should be performed immediately for stenoses in nonculprit arteries is controversial.
METHODS: In this multicenter trial, we randomly assigned 706 patients who had multivessel disease, acute myocardial infarction, and cardiogenic shock to one of two initial revascularization strategies: either PCI of the culprit lesion only, with the option of staged revascularization of nonculprit lesions, or immediate multivessel PCI. The primary end point was a composite of death or severe renal failure leading to renal-replacement therapy within 30 days after randomization. Safety end points included bleeding and stroke.
RESULTS: At 30 days, the composite primary end point of death or renal-replacement therapy had occurred in 158 of the 344 patients (45.9%) in the culprit-lesion-only PCI group and in 189 of the 341 patients (55.4%) in the multivessel PCI group (relative risk, 0.83; 95% confidence interval [CI], 0.71 to 0.96; P=0.01). The relative risk of death in the culprit-lesion-only PCI group as compared with the multivessel PCI group was 0.84 (95% CI, 0.72 to 0.98; P=0.03), and the relative risk of renal-replacement therapy was 0.71 (95% CI, 0.49 to 1.03; P=0.07). The time to hemodynamic stabilization, the risk of catecholamine therapy and the duration of such therapy, the levels of troponin T and creatine kinase, and the rates of bleeding and stroke did not differ significantly between the two groups.
CONCLUSIONS: Among patients who had multivessel coronary artery disease and acute myocardial infarction with cardiogenic shock, the 30-day risk of a composite of death or severe renal failure leading to renal-replacement therapy was lower among those who initially underwent PCI of the culprit lesion only than among those who underwent immediate multivessel PCI. (Funded by the European Union 7th Framework Program and others; CULPRIT-SHOCK ClinicalTrials.gov number, NCT01927549 .).
参考来源
- Thiele H, Akin I, Sandri M, et al. PCI Strategies in Patients with Acute Myocardial Infarction and Cardiogenic Shock. N Engl J Med. 2017. PMID: 29083953. doi:10.1056/NEJMoa1710261
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。